KCI Expands Surgical Incision Management Offering in Europe
KCI, an Acelity Company, today announced the availability of two additional PREVENA™ Therapy offerings in Europe: the PREVENA DUO™ Incision Management System with PEEL & PLACE™ Dressing - 13cm and PREVENA PLUS PEEL & PLACE™ Incision Management System – 35cm. Both of the new introductions incorporate the proven clinical benefits of PREVENA™ Therapy, providing clinicians with solutions to meet the evolving needs of post-surgical incision management. PREVENA™ Therapy helps hold incision edges together and protects incisions from external infectious sources.
The PREVENA DUO™ System is the first single use negative pressure wound therapy (NPWT) system designed specifically for the simultaneous management of two closed surgical incisions, configured to help reduce post-operative complications in bilateral procedures, such as vascular harvesting, breast reconstruction and orthopedic trauma surgeries.
PREVENA PLUS PEEL & PLACE™ System – 35cm is suitable for long incisions commonly used in revision surgery, while also providing higher exudate storage capacity. The PREVENA PLUS™ System offers the proven effectiveness of negative pressure wound therapy with improved versatility, portability, and flexibility.
“Surgical site infections are an issue plaguing heath systems, clinicians and patients around the world,” said R. Andrew Eckert, Chief Executive Officer, KCI. “The ever-growing body of evidence supporting PREVENA™ Therapy continues to demonstrate its efficacy in lowering the incidence of SSIs. In line with our unwavering commitment to patients and our goal of moving healing forward, we hope that as a result of the availability of these two new products, more European patients will be able to benefit from PREVENA™ Therapy and reduce the burden of SSIs.”
“The impact surgical site infections have on patients its significant - delaying their recovery and return to work, causing financial worry and affecting their mental health,” Ron Silverman, M.D., FACS, Chief Medical Officer, KCI. “For those patients who are at increased risk of post-operative complications we need to look carefully at their care to ensure that they recover quickly and effectively. We are proud to be able to introduce the PREVENA DUO™ System and PREVENA PLUS PEEL & PLACE™ System – 35cm in Europe, helping provide clinicians with the tools needed to best serve their patients and provide quality care.”
Surgical site infections (SSIs) present a significant burden in Europe, with more than 500,000 cases in Europe each year.1 SSIs are associated with longer post-operative hospital stays, reduced patient quality of life, may necessitate additional surgical procedures, may require intensive care, and can result in higher morbidity and mortality.2 Infections, the most common surgical site complication, account for up to 20 percent of all of healthcare-associated infections and cost the NHS up to £700 million each year.3,4
Recently, the National Institute for Health and Care Excellence (NICE) published a Medtech Innovation Briefing (MIB) on PREVENA™ Incision Management System. The MIB assesses the most recent published evidence on the technology and surmises that PREVENA™ Therapy can lead to significantly reduced incision site complications in comparison to standard care dressings. Clinical specialists invited to add comment in the report also agreed that using PREVENA™ Therapy would likely lead to cost savings as a result of the reduction in surgical site complications (SSCs) and a reduced need for dressing changes.5
About PREVENA™ Incision Management System
The PREVENA™ System, launched in 2010, is the first disposable negative pressure system designed specifically for the management of closed surgical incisions. The PREVENA™ Incision Management System protects the incision from external contamination, helps hold incision edges together, removes fluid and infection materials, and delivers continuous negative pressure at -125mmHg for up to seven days.
Please refer to the PREVENA™ Incision Management System instructions for use for important limitations and safety information.
About KCI, an Acelity Company
KCI, an Acelity Company, is a well trusted brand in advanced wound care. We are a leader in negative pressure wound therapy, providing solutions for both wound healing and surgical management. Our product offerings are available in more than 90 countries and deliver value through solutions that speed healing. KCI is a leader in quality, safety and customer experience and is committed to advancing the science of healing. Headquartered in San Antonio, Texas, KCI employs approximately 4,500 people worldwide.
2 Cassini A, Plachouras D, Eckmanns T, Abu Sin M, Blank H-P, Ducomble T, et al. (2016) Burden of Six Healthcare-Associated Infections on European Population Health: Estimating Incidence-Based Disability-Adjusted Life Years through a Population Prevalence-Based Modelling Study. PLoS Med 13(10): e1002150. https://doi.org/10.1371/journal.pmed.1002150
3 National Institute for Health and Care Excellence. Clinical guideline CG74. Surgical site infections: prevention and treatment. April 2019. Available at: https://www.nice.org.uk/guidance/ng125. Accessed July 15, 2019.
4 Leaper DJ, van Goor H, Reilly J et al. Surgical site infection - a European perspective of incidence and economic burden. Int Wound J 2004; 1: 247–735. Available at: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1742-4801.2004.00067.x
5 National Institute for Health and Care Excellence. Prevena incision management system for closed surgical incisions. Medtech innovation briefing. 28 February 2019. Available at: https://www.nice.org.uk/advice/mib173. Accessed July 15, 2019.
Phone: +1 (210) 255-6433
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration23.8.2019 23:01:00 EEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the closing of the global research and development collaboration agreement signed on July 14, 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190823005335/en/ This agreement has received clearance from the U.S. Federal Trade Commission under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and merger control approval from the Austrian Federal Competition Authority. Under the terms of the agreement, the closing of this transaction triggers an upfront license fee payment of $3.95 billion by Gilead to Galapagos. In addition, Gilead has made an equity investment in Galapagos of approximately $1.1 billion (or approximately €960 million) by subscribing for new shares at a price of €140.59 per share, including issuance premium. As a result, Gilead now owns 13,589,686 ordinary shares of Galapagos, representing approximately 2
32 Leading Global Fashion and Textile Companies Make Commitments on Climate, Biodiversity and Oceans23.8.2019 10:47:00 EEST | Press release
Ahead of the G7 meeting at Biarritz from August 24-26, French President Emmanuel Macron, accompanied by Economy and Finance Minister Bruno Le Maire, Minister of Labour Muriel Pénicaud, and Deputy Minister of Ecological and Solidary Transition Brune Poirson, has invited to the Elysée Palace representatives of the 32 fashion and textile companies who have launched the Fashion Pact by his side. In April 2019, ahead of the G7 meeting, Emmanuel Macron had given François-Henri Pinault, Chairman and Chief Executive Officer of Kering (Paris:KER), a mission to bring together the leading players in fashion and textile, with the aim of setting practical objectives for reducing the environmental impact of their industry. In a historic move, given the scale and importance of the coalition that has been created, 32 leading companies from the fashion and textile industry have given themselves a set of shared objectives in the form of a Fashion Pact. The coalition includes groups and brands in Luxury,
Ethereum (ETH) Now Available on bitFlyer Buy/Sell23.8.2019 08:00:00 EEST | Press release
Cryptocurrency exchange bitFlyer has announced it is adding Ethereum (ETH) to its Buy/Sell trading platform. From today, bitFlyer Buy/Sell users across Europe and the US can send and receive ETH while ensuring they adhere to the same robust regulatory standards as bitFlyer guarantees for Bitcoin (BTC) transactions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190822005486/en/ Ethereum (ETH) Now Available on bitFlyer Buy/Sell (Graphic: Business Wire) Andy Bryant, Co-head and COO, bitFlyer Europe, said, “At bitFlyer, we want to offer not just the most popular coins, but the most respected ones too, which makes ETH a logical choice to expand our service offering. Not only has ETH proved itself as a useful altcoin, particularly in relation to smart contracts, it has an incredibly strong community that surrounds it. We’re committed to offering the best customer experience whilst prioritising security and regulatory standards, a
STALICLA Announces Completion of pre-IND Meeting With FDA on STP1 for Subgroup of Patients With Autism Spectrum Disorder (ASD)23.8.2019 03:00:00 EEST | Press release
STALICLA, a Swiss Biotech company, today announced the completion of its pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) on the preparation for entry of STP1 into clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190822005559/en/ STALICLA at the Food and Drug Administration (FDA) to discuss its investigational precision medicine for Autism Spectrum Disorder (Photo: STALICLA) “We are appreciative of FDA´s technical guidance and strong interest in personalized medicine approaches for patients with Autism Spectrum Disorder. STALICLA is committed to rapidly move forward with the submission of its STP1 IND. STP1 holds the potential to become the first precision medicine for a subgroup of patients with ASD, and herald a new age for this field.” - Lynn Durham, CEO and Founder of STALICLA. ASD is a common neurodevelopmental disorder, with high level of heterogeneity, that aff
San Fang Chemical Switches to Rimini Street Support for its Oracle EBS and Oracle Database Software23.8.2019 01:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that San Fang Chemical Co., Ltd., a global manufacturer and distributor of artificial leather products headquartered in Taiwan, has switched to Rimini Street support for its Oracle E-Business Suite application and Oracle Database software. In addition to immediately saving 50% of its annual maintenance costs that they were previously paying the vendor, the company can now maintain its core, robust Oracle system for a minimum of 15 years from the time that they switched to Rimini Street support with no forced upgrades. San Fang Chemical has also been able to liberate its IT resources and divert its substantial cost savings to invest in more forward-looking innovation projects to help pave the way for future growth and competitive advantage. This press release features mu
Gravity Unveils its Future Plans During Gamescom 201922.8.2019 18:46:00 EEST | Press release
Gravity Interactive, Inc., a subsidiary of Gravity Co., Ltd. (NASDAQ: GRVY) which is a leading global game company, participated in Gamescom which is one of the three largest game fairs in the world, held in Cologne, Germany from August 20th to 24th. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190822005507/en/ Gravity Interactive, Inc., a subsidiary of Gravity Co., Ltd. (NASDAQ: GRVY) which is a leading global game company, participated in Gamescom which is one of the three largest game fairs in the world, held in Cologne, Germany. At the fair, Gravity announced that it plans to launch ‘Ragnarok M: Eternal Love’ in the European region on September 4th 2019. ‘Ragnarok M: Eternal Love’ will be launched in Russia and Turkey, as well as Europe and it will be serviced in seven languages including English, Portuguese, Spanish, Russian, German, French, and Turkish. (Photo: Business Wire) On August 20th, Gravity held a presentati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom